Bethany Sensenig Sells 5,369 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Key Points

• Director Bethany Sensenig sold 5,369 shares of Supernus Pharmaceuticals at an average price of $42.25, totaling approximately $226,840.
• Analysts have upgraded Supernus Pharmaceuticals, with Cantor Fitzgerald raising its price target from $42.00 to $46.00 and assigning an "overweight" rating.
• Institutional investors have shown increased interest, with firms like Raiffeisen Bank and Versant Capital Management acquiring new stakes in Supernus Pharmaceuticals.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) Director Bethany Sensenig sold 5,369 shares of the business's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.25, for a total transaction of $226,840.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock traded up $0.30 during trading hours on Monday, reaching $42.99. 682,108 shares of the stock were exchanged, compared to its average volume of 638,685. The firm has a market capitalization of $2.41 billion, a P/E ratio of 37.38 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $43.73. The business's fifty day moving average is $34.38 and its two-hundred day moving average is $33.50.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on SUPN shares. Cantor Fitzgerald boosted their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Raiffeisen Bank International AG acquired a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $25,000. Financial Management Professionals Inc. purchased a new position in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $30,000. Versant Capital Management Inc raised its position in shares of Supernus Pharmaceuticals by 6,931.3% during the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 1,109 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Supernus Pharmaceuticals in the 4th quarter valued at approximately $42,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Supernus Pharmaceuticals during the 1st quarter valued at $41,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.